UK:
Material Adverse Change/MAC
09 November 2011
Reed Smith (Worldwide)
To print this article, all you need is to be registered or login on Mondaq.com.
MAC clauses act as a "catch all" provision and aim to
allow a lender to call a default if there is an adverse change
either in the borrower's position or circumstances or in the
wider environment after a defined date.
It is extremely difficult to rely on a MAC clause in practice,
in particular when the relevant event or occurrence affects not
only the borrower but other companies more generally. The Takeover
Panel have said that:
"meeting [its material significance] test requires an
adverse change of very considerable significance striking at the
heart of the purpose of the transaction in question, analogous ...
to something that would justify frustration of a legal
contract" (Panel Statement 2001/15 of 6th November,
2001).
Very few lenders would contemplate seeking to rely on a MAC
clause because the risk of litigation for a lender relying on that
provision, either as a drawstop or an acceleration event, is
high.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Finance and Banking from UK
Asset Recovery Comparative Guide
Bird & Bird
Asset Recovery Comparative Guide for the jurisdiction of UK, check out our comparative guides section to compare across multiple countries
FCA's Consultation Paper
Cadwalader, Wickersham & Taft LLP
Since 3 January 2018, firms that provide portfolio management or investment advice on an independent basis must pay for the research they obtain...
Regulation Round Up
Proskauer Rose LLP
Welcome to the UK Regulation Round Up, a regular bulletin highlighting the latest developments in UK and EU financial services regulation.
FCA To Permit Research Bundling
Akin Gump Strauss Hauer & Feld LLP
The Financial Conduct Authority (FCA) is seeking views on proposed rules that would allow asset managers to opt for bundled payments for third-party investment research, reversing a significant aspect of the UK's implementation of research rules under the Markets in Financial Instruments Directive (MiFID II).